From: Does the “obesity paradox” exist after transcatheter aortic valve implantation?
Variable | Overall (n = 109) | BMI (kg/m2) | ||
---|---|---|---|---|
< 21.9 (n = 27) | 21.9–27.0 (n = 55) | > 27.0 (n = 27) | ||
30-day Mortality | 5 (4.6%) | 1 (3.7%) | 3 (5.5%) | 1 (3.7%) |
Cerebrovascular accident/transient ischemic attack | 3 (2.8%) | 1 (3.7%) | 1 (1.8%) | 1 (3.7%) |
Myocardial infarction | 2 (1.8%) | 0 (0.0%) | 1 (1.8%) | 1 (3.7%) |
Respiratory failure | 7 (6.4%) | 2 (7.4%) | 3 (5.5%) | 2 (7.4%) |
Cardiogenic shock | 3 (2.8%) | 1 (3.7%) | 2 (3.6%) | 0 (0.0%) |
Cardiac tamponade | 1 (0.9%) | 1 (3.7%) | 0 (0.0%) | 0 (0.0%) |
Major bleeding | 2 (1.8%) | 1 (3.7%) | 1 (1.8%) | 0 (0.0%) |
Major vascular complications | 4 (3.7%) | 1 (3.7%) | 2 (3.6%) | 1 (3.7%) |
Minor vascular complications | 8 (7.3%) | 4 (14.8%) | 3 (5.5%) | 1 (3.7%) |
New permanent pacemaker implantation | 7 (6.4%) | 2 (7.4%) | 3 (5.5%) | 2 (7.4%) |
Acute kidney injury stage 3 | 13 (11.9%) | 4 (14.8%) | 7 (12.7%) | 2 (7.4%) |
New York Heart Association functional class | 1.83 ± 0.7 | 1.81 ± 0.9 | 1.83 ± 0.9 | 1.80 ± 0.7 |